|Day Low/High||145.18 / 152.48|
|52 Wk Low/High||90.14 / 179.65|
Biotech stocks are buried in a deep hole. To climb out, companies will have to generate some positive news.
Levi & Korsinsky, LLP announces that it has commenced an investigation of GW Pharmaceuticals plc ("GW Pharmaceuticals" or "the Company") (NASDAQ:GWPH) concerning possible violations of federal securities laws by the...
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer says Macy's should benefit from the cold weather and energy stocks are still 'too dangerous' to put money into.
Legalized cannabis is now the fastest-growing industry in the U.S. We highlight a "green rush" stock that analysts say will soar 124% next year.
Cramer is sticking with Bristol-Myers, is avoiding Marathon Oil and is a believer in Cypress Semiconductor.
There are haves and have-nots in every industry this year, Cramer says.
Cramer calls Raytheon one of the best military plays and GW Pharmaceuticals one of the most speculative stocks.
While some investors are throwing back all their cards and giving up, the skilled players are keeping what works and augmenting their hands with what'll keep working, Cramer says.
From the floor of the NSYE on Wednesday, Jim Cramer answered viewers' questions on the stock market, including questions on Tesla, Chipotle, Ford, PayPal, Under Armour and Lockheed Martin.
TheStreet's Jim Cramer tackled viewer questions on the economy from the NYSE Wednesday. His first viewer question was from Henry Blodget, an investor and CEO of Business Insider.
-Change to After Market on 7 December to Facilitate Inclusion of Additional Epidiolex Data-
Cramer likes Johnson & Johnson, Stryker and Edwards Lifesciences, while avoiding all Chinese stocks.
When interest rates begin to rise, it may be harder to find winners, Cramer said. But only a pessimist would stop looking.
Cramer says you have to be willing to take some pain on Radius Health and GW Pharmaceuticals.
It's government shutdown season and that's never good for the stock market, Cramer says. So he'll be watching Washington as well as earnings from Johnson & Johnson and Wells Fargo.
Cramer favors Costco over Wal-Mart and sees GW Pharmaceuticals as a long-term holding.
Cramer will be watching a plethora of economic data and earnings from Vail Resorts, Paychex and General Electric, among others.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
GW Pharma's drug showed impressive results for treating schizophrenia, Cramer says. Investors looking to buy high-quality consumer companies like Kimberly-Clark should wait for the Fed's rate decision.
Rite Aid and GW Pharmaceuticals both have positive catalysts — and bullish analyst coverage — to help push their share prices higher, Cramer says.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.